研究称:食用大麻软糖数小时后仍会影响驾驶能力
Cannabis Gummies Harm Driving Performance Hours After Use, Study Says

原始链接: https://www.zerohedge.com/medical/cannabis-gummies-harm-driving-performance-hours-after-use-study-says

发表在《美国医学会杂志·网络开放版》(JAMA Network Open)上的一项最新研究显示,食用大麻会显著损害驾驶能力。研究人员通过驾驶模拟器,对 40 名服用不同剂量四氢大麻酚(THC)的参与者进行了分析。结果表明,在食用后长达五小时内,摄入 10 毫克和 20 毫克剂量会导致驾驶者难以保持车道、反应时间变慢以及对车速的控制能力下降。 关键在于,该研究发现,即使驾驶表现已出现明显受损,血液中的四氢大麻酚浓度往往仍低于或接近常见的路边执法阈值。这表明当前的检测标准可能无法准确判定受损程度。该研究的合著者克里斯汀·威肯斯(Christine Wickens)博士提醒,许多使用者低估了这些影响,并强调需提高警惕。 随着大麻相关法规的演变,这一发现凸显了一个日益严峻的安全问题。美国卡车运输协会等行业团体已表示,对缺乏可靠且标准化的评估大麻相关驾驶受损的方法感到担忧。这些结果强化了社会共识,即食用大麻会导致关键驾驶技能出现显著且可测量的衰退,从而对公共道路安全构成风险。

相关文章

原文

Authored by Naveen Athrappully via The Epoch Times,

The use of commercially available cannabis edibles impairs people's driving ability, even after several hours of consumption, a study has found.

Published in the JAMA Network Open journal on Aug. 31, the peer-reviewed study looked at simulated driving performance after the consumption of cannabis edibles.

Conducted in a Canadian hospital, the study analyzed data of 40 people aged 19-45 years. They received gummies containing delta-9-tetrahydrocannabinol (THC) - the main psychoactive chemical in cannabis that causes brain-altering effects. Various combinations of THC and placebo edibles were given to achieve four doses of THC exposure - 0 mg, 2 mg, 10 mg, and 20 mg.

The study measured the standard deviation of lateral position (SDLP), which assesses how drivers adjust lane position and is used to evaluate the effects of medicines and illegal drugs.

Researchers found that SDLP was "significantly increased" at 20 mg and 10 mg doses compared with the placebo at two and five hours post-consumption, suggesting greater difficulty in maintaining lane position.

Reaction time and the standard deviation of speed were "negatively influenced" among drivers due to THC exposure, the study said. The individual's willingness to drive was also found to have "significantly decreased" at 20 mg exposure, according to the study.

For the highest dose of 20 mg, whole-blood THC concentrations peaked at 3.4 nanograms per milliliter (ng/mL). This falls within the 1 to 5 ng/mL limits for drivers set by some U.S. states.

The Centre for Addiction and Mental Health in Toronto highlighted the link between driving impairment and blood THC levels in an Aug. 31 statement.

All peak blood THC concentrations in the study were below or near common thresholds used for roadside enforcement, the statement said. This was true even among those who consumed the highest dose.

"Many people may underestimate the impairment caused by cannabis edibles," Dr. Christine Wickens, co-author of the study, said in the statement. "Our findings show that commonly consumed doses can significantly affect critical driving skills, reinforcing the need for caution when making decisions about driving after use."

The study was funded by a grant from Public Safety Canada. Two authors reported conflicts of interest, including receiving grants from pharmaceutical companies.

In an April 20 statement, the University of Colorado Anschutz also reported similar findings. In these studies, people were made to use a driving simulator before and after consuming cannabis.

Cannabis was found to affect driving performance, especially lane-control measures, such as lane departures and weaving. Inhaling cannabis showed smaller and less consistent changes, while edible cannabis resulted in "more noticeable impairment, including slower speeds and increased lane variability and departures," the statement said.

In the United States, the Trump administration recently reclassified cannabis, or marijuana, under the Controlled Substances Act. On April 23, the Department of Justice and the Drug Enforcement Administration announced placing some cannabis products under Schedule III of the Act.

Schedule III drugs are deemed to have lower abuse potential and are accepted for medical use. The classification is only applicable to cannabis items approved by the Food and Drug Administration or regulated by a state medical marijuana license.

The American Trucking Associations (ATA) has raised concerns about public safety risks arising from the reclassification.

In an April 24 statement, Brenna Lyles, ATA's vice president of safety policy, highlighted concerns about rescheduling cannabis without proper safeguards to preserve the U.S. Department of Transportation's (USDOT's) testing authority for workers carrying out safety-sensitive jobs.

"Absent clear protections for USDOT's marijuana testing authority, a policy shift could undermine the Department's drug- and alcohol-testing program and weaken highway safety," Lyles said.

"That risk is compounded by the lack of a reliable, widely accepted standard to measure marijuana impairment, whether roadside or before a driver gets behind the wheel."

联系我们 contact @ memedata.com